Sun Pharma Q1: sales +10.5%, but EBITDA margin slips to 28.9% and adjusted PAT up only ~3%

Sun Pharma opened FY27 with consolidated revenue of ₹15,300 Cr, up 10.5% YoY (+4.7% QoQ), a healthy topline print led by India formulations (+16% to ₹5,475 Cr, taking Pharmarack market share to 8.5% from 8.2%) and Global Innovative Medicines (+12.8% to US$351 mn, 21.9% of sales). Reported consolidated PAT of ₹2,895 Cr looks striking at +26% YoY, but that jump is almost entirely a base effect: the year-ago quarter absorbed a ~₹717 Cr net exceptional loss (Taro's US$62 mn EPP legal settlement plus the SCD-044 write-off), while this quarter carries a smaller ₹195 Cr net exceptional (₹167 Cr Organon deal costs and a labour-code charge). Stripping both sides out, adjusted PAT of ₹3,089 Cr grew just 3.1% — the number the print should be judged on. The real operational signal is margin, not headline profit. EBITDA rose only 2.7% to ₹4,418 Cr and EBITDA margin compressed 220 bps to 28.9% from 31.1% a year ago, even as gross margin ticked up to 80.5%. The squeeze sits below the gross line — employee costs (+15% YoY) under the New Labour Codes and elevated launch-related spend for LEQSELVI/UNLOXCYT, which management had flagged as factored into the FY27 plan. R&D was ₹826 Cr at 5.4% of sales, running below the 6–7% the company guided, softening the reported margin further. Geography drove the mix: US formulations fell 9.7% YoY to US$427 mn as generics (including lenalidomide) eroded, only partly cushioned by innovative medicines; Emerging Markets grew 4.2% and RoW was flat. This is why consolidated revenue (+10.5%) far outpaced standalone (+2.6% to ₹5,741 Cr) — the India entity is steady but subsidiary/specialty momentum carries the group. Against the ~11% revenue and 7–11% PAT-decline that street previews modelled, the topline landed roughly in line and margins beat the 26–27.5% preview band, while underlying profit growth (~3%) undershot the double-digit hopes some carried in. The quarter also advanced the strategic agenda: Organon shareholders approved the US$11.75 bn acquisition on July 24, and management reiterated a close by Q4FY27/early 2027 — with more transaction costs to come. Semaglutide approvals in Brazil and South Africa and a maintained US$3.4 bn net-cash position round out a quarter where the strategy progressed but the P&L, on a like-for-like basis, was steady rather than strong.